Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Revenue: 2012-2024

Historic Revenue for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $267.0 million.

  • Coherus Oncology's Revenue rose 91.19% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.7 million, marking a year-over-year increase of 152.07%. This contributed to the annual value of $267.0 million for FY2024, which is 3.78% up from last year.
  • As of FY2024, Coherus Oncology's Revenue stood at $267.0 million, which was up 3.78% from $257.2 million recorded in FY2023.
  • Coherus Oncology's 5-year Revenue high stood at $475.8 million for FY2020, and its period low was $211.0 million during FY2022.
  • Over the past 3 years, Coherus Oncology's median Revenue value was $257.2 million (recorded in 2023), while the average stood at $245.1 million.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 33.63% in 2020, then tumbled by 35.37% in 2022.
  • Yearly analysis of 5 years shows Coherus Oncology's Revenue stood at $475.8 million in 2020, then tumbled by 31.37% to $326.6 million in 2021, then plummeted by 35.37% to $211.0 million in 2022, then climbed by 21.89% to $257.2 million in 2023, then increased by 3.78% to $267.0 million in 2024.